drugset
drugset / Trial / NCT03202147

Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)

NCT03202147 ↗

Phase 2 Withdrawn AZTherapies, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase II, randomized, double-blinded, placebo-controlled study for subjects with evidence of PSCI.

Timeline

Start
2023-12
Primary completion
2024-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cromolyn Small molecule 17.1 mg Inhaled

Indications

cognitive disorder ischemic stroke